Results 71 to 80 of about 15,824 (192)
Frontiers in Microbiology, 2022 Ceftazidime/avibactam (CZA) is an alternative antibiotic used for the treatment of infections caused by carbapenem-resistant Enterobacterales (CRE). However, the CZA-resistant CRE strains have been detected worldwide.
Weiliang Zeng +10 more
doaj +1 more source
MicrobiologyOpen, Volume 15, Issue 2, April 2026.This study shows a strong correlation between the β‐lactam susceptibility profile of a clinical isolate of Nocardia cyriacigeorgica and the activity of its β‐lactamase, NCY‐1. Inhibitors of NCY‐1 reduce the minimum inhibitory concentration of amoxicillin.
Julie Couston +8 more
wiley +1 more source
Empiric antibiotic therapy in urinary tract infection in patients with risk factors for antibiotic resistance in a German emergency department [PDF]
, 2018 Background: The aim of this study was to identify clinical risk factors for antimicrobial resistances and multidrug resistance (MDR) in urinary tract infections (UTI) in an emergency department in order to improve empirical therapy. Methods: UTI cases
Bischoff, Sebastian +4 more
core +1 more source
Bacteriophage Therapy: Current Strategies and Future Perspectives
MedComm, Volume 7, Issue 3, March 2026.This manuscript systematically reviews the expanding scope of phage applications. It moves beyond traditional antibacterial use to explore their role in precision therapies against drug‐resistant infections, their synergy with antibiotics, and advanced biomaterial‐assisted delivery systems.
Zihe Zhou +7 more
wiley +1 more source
mBioβ-Lactamases can accumulate stepwise mutations that increase their resistance profiles to the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an Escherichia coli clinical strain isolated from a patient who underwent ...
Akito Kawai +10 more
doaj +1 more source
Carbapenemase-producing organisms: a global scourge [PDF]
, 2018 The dramatic increase in the prevalence and clinical impact of infections caused by bacteria producing carbapenemases is a global health concern.
Bonomo, Robert A +6 more
core
Selection of mutants with resistance or diminished susceptibility to ceftazidime/avibactam from ESBL- and AmpC- producing Enterobacteriaceae [PDF]
, 2018 Introduction: Difficult Gram-negative infections are increasingly treated with new β-lactamase inhibitor combinations, e.g. ceftazidime/avibactam.
Doumith, Michel +5 more
core +1 more source
Necrotising Soft Tissue Infections: A Single Center's Case Series
International Wound Journal, Volume 23, Issue 3, March 2026.ABSTRACT Necrotising soft tissue infection (NSTI) is a progressive disease with a time‐dependent prognosis; if not promptly treated, it can lead to significant morbidity as well as mortality. Early and aggressive surgical treatment is mandatory for appropriate management. This study reports the diagnostic and therapeutic pathway, surgical treatment and
Francesca Toia +6 more
wiley +1 more source
Interactions between Avibactam and Ceftazidime-Hydrolyzing Class D β-Lactamases
Biomolecules, 2020 Class D β-lactamases exhibit very heterogeneous hydrolysis activity spectra against the various types of clinically useful β-lactams. Similarly, and according to the available data, their sensitivities to inactivation by avibactam can vary by a
Jean-Marie Frère +6 more
doaj +1 more source
Crystal structure of the Pseudomonas aeruginosa BEL-1 extended-spectrum β-lactamase and its complexes with moxalactam and imipenem [PDF]
, 2016 BEL-1 is an acquired class A extended-spectrum β-lactamase (ESBL) found in Pseudomonas aeruginosa clinical isolates from Belgium which is divergent from other ESBLs (maximum identity of 54% with GES-type enzymes).
Benvenuti, Manuela +7 more
core +1 more source